The number of notified cases of invasive pneumococcal disease (IPD) in the second quarter of 2018 was greater than the previous quarter, and slightly higher than the second quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident.
serotype included in the 13vPCV, similar to the previous quarter (44%; 12/27) and the second quarter of 2017 (50%; 28/56) ( Figure 2 ). The most frequent serotypes among cases aged less than 5 years this quarter were serotype 19A (20%; 12/59) and 3 (19%; 11/59), both of which are included in the 13vPCV. Of the 27 cases aged less than 5 years with 13vPCV serotypes, 19 cases were fully vaccinated and considered to be 13vPCV failures. These 13vPCV failures were due to serotypes 19A (n=10), 3 (n=7), 19F (n=1) and 23F (n=1) ( Table 4 ).
Among Indigenous Australians aged 50 years and over, there were 16 cases of IPD reported this quarter. Of those cases with a reported serotype (n=13), 10 (77%) were due to a serotype included in the 23vPPV (Figure 3) . Whilst there were a number of serotypes reported amongst this group this quarter, the majority only had one case attributed, except for serotype 22F where there were 4 cases reported. The number of notified cases of IPD in this population group was similar to the number of cases reported in the previous quarter (n=15), and slightly lower than the number reported in the second quarter of 2017 (n=18).
Among non-Indigenous Australians † aged 65 years and over there were 191 cases of IPD reported this quarter. The number of notified cases of IPD in this population group were two times higher compared to the number of cases reported in the previous quarter (n=94) and slightly higher than the number reported in the second quarter of 2017 (n=187). Of those cases with a reported serotype (n=162), 56% (91/162) were due to a serotype included in the 23vPPV (Figure 4 ). This was similar to the proportion in the previous quarter (56%; 47/83) and slightly lower than the second quarter of 2017 (61%; 109/178). For this quarter, serotypes 3 (n=21), 23A (n=17) and 6C (n=15) were the most common serotypes for this population group. Only serotype 3 is included in the 23vPPV.
During this quarter there were 36 deaths attributed to a variety of IPD serotypes. Seventeen (47%) of the cases had a serotype covered by currently available pneumococcal vaccines, 15 were due to a non-vaccine serotype, and four were reported as being untyped. All of the reported deaths this quarter occurred in non-Indigenous Australians † . The median age of those cases reported to have died this quarter was 81 years (range 39 to 101 years). † Non-Indigenous Australians includes cases reported with an Indigenous status of non-Indigenous, not stated, blank or unknown. 
Notes
The data in this report are provisional and subject to change as laboratory results and additional case information become available. More detailed data analysis of IPD in Australia and surveillance methodology are described in the IPD annual report series published in Communicable Diseases Intelligence.
In Australia, pneumococcal vaccination is recommended as part of routine immunisation for children, individuals with specific underlying conditions associated with increased risk of IPD and older Australians. More information on the scheduling of the pneumococcal vaccination can be found on the Immunise Australia Program website (www.immunise.health.gov.au).
In this report, a 'vaccine failure' is reported when a child aged less than 5 years is diagnosed with IPD due to a serotype found in the 13vPCV and they have received 3 primary scheduled doses of 13vPCV at least 2 weeks prior to disease onset with at least 28 days between doses of vaccine.
There are 3 pneumococcal vaccines available in Australia, each targeting multiple serotypes ( Table 5 ). Note that in this report serotype analysis is generally grouped according to vaccine composition.
Follow-up of all notified cases of IPD is undertaken in all states and territories except New South Wales and Victoria who conduct targeted follow-up of notified cases aged under 5 years, and 50 years or over for enhanced data. Followup of notified cases of IPD in Queensland is undertaken in all areas except Metro South and Gold Coast Public Health Units who conduct targeted follow-up of notified cases for those aged under 5 years only. However, in these areas where targeted case follow-up is undertaken, some enhanced data may also be available outside these targeted age groups. 
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